Jefferies Group’s PMV Pharmaceuticals PMVP Stock Holding History

Jefferies Group’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-35,000	Closed	-$499K	–	1869
2022 Q2	$499K	Buy	+35,000	New	+$509K	﹤0.01%	995

Other funds holding PMVP

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Jefferies Group's PMVP Position: Q1 2021 in Review

Jefferies Group sold out of PMV Pharmaceuticals (PMVP) in Q1 2021, closing a stake of 10,000 shares — an estimated $615K sold.

Jefferies Group first reported a position in PMVP in Q4 2020 and held it in 1 quarter. The position peaked at $615K in Q4 2020. 81 funds tracked by Wall St. Rank hold PMVP as of Q1 2021.

Jefferies Group reported no remaining PMV Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Jefferies Group sold 10,000 PMV Pharmaceuticals shares in Q1 2021, an estimated $615K.
Jefferies Group first reported a position in PMV Pharmaceuticals in Q4 2020 and held it in 1 quarter.
Jefferies Group's PMV Pharmaceuticals position peaked at $615K in Q4 2020.
81 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2021.

Based on Jefferies Group's 13F filing for Q1 2021, filed 14 May 2021.